



NuVision and Altacor announce distribution partnership to deliver sight saving treatment

NuVision Biotherapies Limited, a regenerative wound treatment company, and Altacor, a leading ophthalmic specialist, have announced the signing of a strategic partnership to distribute the sight saving therapy, Omnigen, throughout England, Scotland and Wales.



Through this agreement, Altacor will act as the exclusive distributor for the Omnigen product range to healthcare customers, with NuVision providing expert technical, scientific and clinical support. This unique offering of strong UK-based pharma and regenerative medicine is a milestone for ocular surface medicine, and for the future development and dissemination of personalised regenerative therapies.

Dr Andrew Hopkinson, founder and CEO of NuVision, said: “NuVision has partnered with Altacor to provide widespread access to Omnigen for Ophthalmology departments and patients across the country. Since our launch last year, we have already demonstrated significant successes in a small number of NHS and private hospitals in England, using Omnigen to help restore and retain patients sight. Surgeons have found Omnigen to be extremely convenient, easy to use, and effective in the treatment of ocular surface disorders. Through this partnership we will widen access to Omnigen across Great Britain, helping clinicians to save sight and the NHS to save money.

“We are excited to be working with Altacor who share our values of responsive and compassionate patient care. Together, we look forward to offering this groundbreaking regenerative therapy and high quality personal service to every ophthalmic surgeon in Great Britain”

Dr Francesca Crawford, CEO of Altacor, said: “This is a very significant partnership for Altacor which further expands our portfolio in the ophthalmic surgical area, adding to the viscoelastic Biolon and other imminent new launches. Omnigen is a fascinating and pioneering product which we are delighted to be working with, especially in light of the multiplicity of applications and the potential for sight saving.

The complementarity and cooperation between the NuVision and Altacor teams is very strong and we believe will lead to great success."

Dr Susan Huxtable, Director of IP Commercialisation at The University of Nottingham said: *"NuVision has come a long way in a very short period of time and has already benefitted patients. I am delighted that the company has now secured this distribution deal with Altacor, which will help to ensure that the technology reaches many more patients, fully realising the impact of many years of academic research."*

Peter Dines, Investment Director and Head of Life Sciences at Mercia Fund Management, said: *"We are pleased to see NuVision develop this key partnership with Altacor as they continue to commercialise Omnigen and increase access to this innovative treatment."*

For more information about NuVision, visit: www.nu-vision.co.uk

<ENDS>

Notes to Editors

About NuVision

Based in MediCity, Boots Campus, Nottingham, NuVision Biotherapies is a regenerative medicine company recently spun out from Academic Ophthalmology, School of Medicine, University of Nottingham. NuVision was established in 2015, founded on investment from Mercia Fund Management, to develop and bring to market cutting edge and disruptive regenerative therapies. Initially focusing on treating front of the eye disease and trauma, NuVision intend to utilise their expertise to expand into the chronic wound arena.

www.nu-vision.co.uk

Twitter and Instagram @NuVisBio

About Omnigen

Omnigen is a ground-breaking, patented, dry preparation of human-derived amniotic membrane, made from the sac surrounding the baby during pregnancy. The Tereo® manufacturing process transforms this waste product of birth into a sterile and stable dry regenerative therapy that can be easily shipped and accessed anywhere in the world. Omnigen is applied directly to the wound dry and is rapidly and effectively rehydrated using surrounding moisture to immediately reactivate the beneficial properties to promote tissue repair and healing in a variety of ways. The product represents a unique and versatile "off-the-shelf" regenerative product that can be manufactured in a scalable manner, may be stored long term, and is administered without tissue matching or the need for immune suppression. The Tereo process improves the wound healing action and provides surgeons with an effective sight saving therapy that could provide a meaningful benefit to patients, including those suffering from serious sight destroying ocular surface diseases and conditions with unmet medical need.

About Altacor

Altacor is an ophthalmic specialty pharmaceutical company with a portfolio of marketed and development products. The company differentiates its development products primarily through formulation or reprofiling existing compounds with established clinical activity and systemic safety. The products are focused in the following sub-therapeutic areas: ocular surface disease and surgical.

Altacor markets numerous products in the UK and Ireland (Clinitas[®], Clinitas[®] OTC range, Clinitas[®] Hot Eye Compress and Biolon[®]) which are commercialised through its own sales and marketing organisation and network. Clinitas[®], Clinitas[®] Multi and Clinitas GEL are prescription products, including preservative free options. Clinitas products can be used for moderate dry eye conditions and have the highest concentration of hyaluronic acid (0.4%) in the UK. Biolon[®] is high quality viscoelastic for use in cataract surgery with convenient 6 month room temperature storage. The company is actively pursuing European expansion.

About Mercia Fund Management Ltd

Mercia Fund Management provides tax-efficient SEIS & EIS capital to early stage businesses, particularly those residing in the Midlands, the North of England and Scotland.

Mercia Fund Management is an FCA-authorized and regulated fund manager under FSMA (FRN: 524856).

Mercia Fund Management is a wholly owned subsidiary of Mercia Technologies PLC.

www.merciafund.co.uk

About The University of Nottingham

The [University of Nottingham](http://www.nottingham.ac.uk) has 43,000 students and is ‘the nearest Britain has to a truly global university, with a “distinct” approach to internationalisation, which rests on those full-scale campuses in [China](#) and [Malaysia](#), as well as a large presence in its home city.’ (*Times Good University Guide 2016*). It is also one of the most popular universities in the UK among [graduate employers](#) and was named [University of the Year for Graduate Employment](#) in the 2017 The Times and The Sunday Times Good University Guide. It is ranked in the world’s top 75 by the QS World University Rankings 2015/16, and [8th in the UK](#) by research power according to the Research Excellence Framework 2014. It has been voted the world’s greenest campus for [four years running](#), according to Greenmetrics Ranking of World Universities.